Abiraterone for treating metastatic prostate cancer

Published on 01 Oct 2020
Last Updated on 19 Dec 2022

Abiraterone for treating metastatic prostate cancer Guidance and Plain English Summary (PES) is outdated and has been withdrawn on 19 December 2022.
Please refer to the updated recommendations on Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions here.

Abiraterone for treating metastatic prostate cancer (Withdrawn 19 December 2022) [PDF, 262 KB]

PES Abiraterone for treating metastatic prostate cancer (Withdrawn 19 December 2022) [PDF, 201 KB]